À propos de GlycoNet
Qui nous sommes
Comité des Finances et de Vérification
Comité des Nominations
Research Management Committee
Conseil Consultatif Scientifique
Commercialization & Legacy Committee
Equity, Diversity and Inclusion Committee
Comité de Formation
Équité, diversité et inclusion
Le Comité de Gestion de la Recherche supervise le portefeuille de R&D et fait des recommandations au Conseil d'Administration sur le financement des demandes de subventions grant applications. Le comité oriente les directions de la recherche en fonction du plan stratégique global approuvé par le conseil d’administration.
Warren is a Professor from the Department of Biological Sciences at the University of Alberta. The Wakarchuk lab investigates the structure and function of the enzymes which make and degrade various glycoconjugates. This work has been enabling the chemo-enzymatic synthesis of bioactive glycoconjugates both in the laboratory and for industrial projects. The Wakarchuk lab has expertise with both mammalian and bacterial carbohydrate active enzymes for glycan remodelling applications.
Dr. DeAngelis’s research has led to commercial applications, including the design of novel hybrid polysaccharide molecules for medical or industrial applications, the formation of biocompatible coatings and surfaces for use in sensors or other implanted devices, the synthesis of defined oligosaccharides that have potential for use as anticancer agents, anticoagulants, or immune system stimulators and the synthesis of sugar-based targeting drug delivery systems. Dr. DeAngelis is a founding scientist of four life science ventures: Hyalose, Heparinex, Choncept and Caisson Biotech.
Dr. Furneaux is one of New Zealand’s most respected scientists. His team includes 33 research scientists whose achievements include 225 publications, 32 reviews and 13 published patent series. Dr. Furneaux, who holds a PhD in Chemistry from Victoria University of Wellington, is a fellow of both the Royal Society of New Zealand and the New Zealand Institute of Chemistry. In 2006 he was awarded the Hector Medal from the Royal Society for his outstanding contribution to the advancement of carbohydrate chemistry and for achieving world-wide recognition of chemistry and pharmacology in New Zealand.
Professor Nitz’s research program spans the areas of synthetic carbohydrate chemistry and chemical biology. Focusing on bacterial biofilm formation the Nitz lab has efficiently synthesized key carbohydrate adhesin’s that form the structure of the biofilm matrix. These compounds have served as substrates to elucidate the biochemistry and structure of the enzymes required for polysaccharide adhesin synthesis and biofilm formation.
Dr. Plante is Senior Director of Bacterial Immunology at Moderna Therapeutics where he leads the discovery of novel mRNA-based vaccines and antibodies. Previously, Dr. Plante served as Director of Research at Visterra through their acquisition by Otsuka for $430M. At Visterra he led early stage research programs including a CARB-X funded program developing an innovative glycan-targeted antibody-drug conjugate for the treatment of Pseudomonas aeruginosa infections.
Dr. Segura’s laboratory applies multidisciplinary approaches, from biochemistry to cellular and molecular immunology, to dissect the role of bacterial capsular polysaccharides (CPSs) on the immunopathogenesis of the disease caused by pathogenic streptococci.
Dr. Xanthoudakis brings over 27 years of pharmaceutical industry experience, holding various positions at Merck in discovery research, in business development, and as Research Investigator in the Department of Neurogenetics at Hoffman La Roche (NJ, USA). He also served as the Chief Business Development Officer for the Quebec Consortium for Drug Discovery (CQDM) where he managed the execution of numerous R&D deals involving pharma, biotech, and academia.
Dr. West is Professor of Pediatrics, Surgery, Medical Microbiology/Immunology and Laboratory Medicine/Pathology at the University of Alberta. She has long-standing interest and expertise in pediatric heart transplantation and transplant immunology, particularly related to ABO glycobiology. Her pioneering work on crossing ABO-barriers led to global impact on infant heart transplantation. Director of the Alberta Transplant Institute, Dr. West is also founding Director of the Canadian Donation Transplant Research Program (CDTRP), a coalition of 350+ participants at 33 sites across Canada funded by the Canadian Institute of Health Research and partners. Recently, Dr. West was appointed as an Officer of the Order of Canada.
Elizabeth is the CEO of GlycoNet. She was involved in the GlycoNet initiative since the Letter of Intent stage and served as the Associate Director, Business for the Alberta Glycomics Centre from 2007–2015. Prior to her position with the Centre, she worked as a manager of large-scale and multi-institutional projects with Genome Prairie. In addition to her PhD in biochemistry, Elizabeth has an MBA in biotechnology management.
Réseau Canadien de la Glycomique
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
© Réseau Canadien de la Glycomique (GlycoNet). Tous droits réservés.